Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

[1]  M. Hallek,et al.  Anti‐CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial , 2019, British journal of haematology.

[2]  A. LaCasce,et al.  Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia* , 2018, Leukemia & lymphoma.

[3]  E. Kimby,et al.  High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. , 2018, Blood.

[4]  J. Gribben.  How and when I do allogeneic transplant in CLL. , 2018, Blood.

[5]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[6]  A. Zelenetz,et al.  Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States , 2018, Haematologica.

[7]  G. Gordon,et al.  Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jeffrey A Jones,et al.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. , 2018, Blood.

[9]  Jeffrey A Jones,et al.  Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. , 2018, The Lancet. Oncology.

[10]  M. Davids,et al.  Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report , 2017 .

[11]  N. Schmitz,et al.  Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. , 2017, Blood.

[12]  M. Hallek,et al.  Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial , 2017 .

[13]  J. Byrd,et al.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Lade,et al.  Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. , 2017, Blood.

[15]  C. Flowers,et al.  Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Cheson,et al.  Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Maris,et al.  Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial , 2016 .

[18]  J. Gribben,et al.  Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  P. Abrisqueta,et al.  The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial) , 2016, Bone Marrow Transplantation.

[20]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[21]  Jeffrey A Jones,et al.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.

[22]  Jeffrey A Jones,et al.  Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. , 2015, JAMA oncology.

[23]  Susan O'Brien,et al.  Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. , 2015, Blood.

[24]  E. Jabbour,et al.  BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. , 2014, Blood.

[25]  D. Porter,et al.  Novel treatments for chronic lymphocytic leukemia and moving forward. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[26]  Michael Hallek,et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.

[27]  A. Zelenetz,et al.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.

[28]  J. Gribben,et al.  Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome , 2012, Leukemia.

[29]  Alexandra G. Smith,et al.  Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.

[30]  K. Owzar,et al.  Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  J. Radich,et al.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[33]  U. Jäger,et al.  Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies? , 2002, Journal of Clinical Immunology.

[34]  B. Andersson,et al.  Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. , 2004, Experimental hematology.

[35]  U. Jäger,et al.  CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells , 2001, Leukemia.

[36]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.